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Background: The decoction combination of Herba Epimedii and Fructus Ligustri Lucidi has been used to treat
osteoporosis for almost 50 years by practitioners of traditional Chinese medicine. However, it is unclear what
specific effects this combination of herbs has on the skeleton. The aim of this study was to assess the effects of the
combined extracts from Herba Epimedii and Fructus Ligustri Lucidi on the bone turnover and bone mineral
content in a rat model of osteoporosis induced by retinoic acid.
Methods: Fifty male Wistar rats were randomly assigned to the normal control group, osteoporosis model group,
or treatment groups in which osteoporosis was induced and then the combined extracts of Herba Epimedii and
Fructus Ligustri Lucidi were administered at 50, 100, or 200 mg/kg/day for 3 weeks via oral gavage. The rat
osteoporosis model was induced by intragastric administration of 70 mg/kg/day of retinoic acid for 2 weeks. Bone
turnover markers, bone biomechanical properties, and the calcium and phosphorus content of the right tibia and
serum were measured.
Results: The retinoic acid administration decreased the bone mass and the contents of calcium and phosphorus in
the bone mineral, weakened the biomechanical properties, and increased bone turnover by stimulating bone
resorption and collagen metabolism. Treatment with the combined extracts of Herba Epimedii and Fructus Ligustri
Lucidi significantly mitigated the effects of osteoporosis on the rats by decreasing bone metabolism, improving the
bone mineral content, and increasing the biomechanical properties.
Conclusions: The results of this study highlight the anti-osteoporosis effects of the combined extracts of Herba
Epimedii and Fructus Ligustri Lucidi. These findings may contribute to the development of natural anti-osteoporosis
herbal medicines.
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Osteoporosis is one of the most common bone remodel-
ing diseases characterized by a reduction in bone mass
and bone microstructural deterioration [1]. This disease is
caused by an imbalance in bone remodeling, with de-
creased bone formation and increased bone resorption,
which ultimately results in skeletal fragility and an in-
creased risk of hip and vertebral fracture [2]. Osteoporosis
mainly affects post-menopausal women and elderly men
and is one of the most serious threats to public health
[3,4], with an estimated prevalence of 200 million people
worldwide and annual costs exceeding approximately 10
billion dollars [5]. Western medical treatments for osteo-
porosis are somewhat effective, but the long-term use of
those medicines can result in a number of side effects
[6-9], including atraumatic bone fractures caused by
bisphosphonates, increased incidence of coronary heart
disease, stroke, pulmonary embolism, and ovarian and
endometrial cancers caused by estrogen or estrogen re-
placement therapy.
Because of these side effects of the currently available
anti-osteoporosis drugs, the development of herbal medi-
cinal products to treat osteoporosis has become a global
focus, and many studies of natural medicines have been
published [10]. According to the theories of traditional
Chinese medicine (TCM), bone health is considered to be
closely related to kidney function, and “kidney deficiency”
is thought to be the root of all pathologies related to bones
and joints. Thus, the treatment of osteoporosis is achieved
by strengthening the kidney function. The ancient Chinese
medicinal literature indicates that Herba Epimedii
(Yinyanghuo) replenishes kidney-yang and Fructus Ligustri
Lucidi (Nvzhenzi) replenishes kidney-yin. Therefore, they
have been used to strengthen bone and treat osteoporosis
in China for several thousand years. Osteoporosis is a
chronic and complex disease related to kidney-deficiency
syndrome that should be treated with a long-term medical
intervention, but both Yang-tonifying prescriptions, which
have the property of warm dryness, and yin-tonifying pre-
scriptions, which show sticky and greasy properties, are
unsuitable for long-term clinical application. However,
Yang-tonifying herbs matched with the right Yin-tonifying
herbs can make living things grow freely and flourish by
eliminating the side effects of each other. Professor
Shi-Zeng Li, a famous doctor of TCM, has used the de-
coction combination of Herba Epimedii and Fructus
Ligustri Lucidi to treat osteoporosis for almost 50 years
[11]. We previously demonstrated that decoction of
Herba Epimedii and Fructus Ligustri Lucidi reversed
abnormalities in collagen type I and bone metabolism,
increased bone mineral density (BMD) and bone bio-
mechanical properties, and improved the pathological
condition of the bone tissue in rats with osteoporosis
induced by retinoic acid administration. In addition,the effects of combined therapy with Herba Epimedii and
Fructus Ligustri Lucidi were better than with either one
alone. Many studies confirming the anti-osteoporotic ef-
fects of the total flavonoids of Herba Epimedii [12-14] and
the total iridoids and flavonoids extracted from Fructus
Ligustri Lucidi [15-17] have been published.
Based on the work referenced above, the aim of this
study was to assess the anti-osteoporosis effects of com-
bined extracts of Herba Epimedii and Fructus Ligustri
Lucidi on the retinoic acid-induced rat osteoporosis model
by measuring bone turnover markers, bone biomechanical
properties, and bone mineral content after treatment.
Methods
Preparation of herbal extracts
Herba Epimedii, the dried leaf of Epimedium brevicornum
Maxim, and Fructus Ligustri Lucidi, the dried mature seed
of Ligustrum lucidum Ait, were purchased from Beijing
Tongrentang Pharmaceutical Co. Ltd., China, and authen-
ticated by an expert herbalist at Capital Medical Univer-
sity. The plant matter was stored in a dry and sealed
container at 4°C.
Herba Epimedii (1000 g) was extracted three times
with 90% ethanol (10 L) for 3, 2, and 2 hours at 70°C in
a reflux apparatus. The extracts were mixed, filtered,
and concentrated under reduced pressure until recovery
showed no alcohol precipitation. Next, they were ex-
tracted with petroleum ether three times to remove any
chlorophyll and then washed with D-101 macroporous
resin until becoming colorless, eluted with 90% ethanol,
and steamed to yield a dark yellow powder containing
the total flavonoids of Herba Epimedii (TFE). The yield
of TFE was 2.5%. Based on the phytochemical test
(Pharmacopeia of the People’s Republic of China, 2010
Edition), the content of TFE was 80%, calculated using
Icariin as a standard.
Fructus Ligustri Lucidi (1000 g) was extracted three
times with 75% ethanol (10 L) for 3, 2, and 2 hours at 70°
C in a reflux apparatus. The extracts were mixed, filtered,
and concentrated under reduced pressure until recovery
showed no alcohol precipitation. Using AB-8 macropor-
ous resin, the extracts were washed with distilled water
and then with 75% ethanol. The steamed extracts included
the total iridoids and flavonoids of Fructus Ligustri Lucidi
(TIFL), which appeared as a dark yellow powder. The yield
of TIFL was 5%. Based on the phytochemical test
(Pharmacopeia of the People’s Republic of China, 2010
Edition), the content of TIFL was greater than 80%, as cal-
culated using Oleanolic Acid and Rutin as standards [11].
The Herba Epimedii and Fructus Ligustri Lucidi ex-
tracts were combined at a ratio of 2 to 3 (TFE to TIFL),
equivalent to a ratio of 4 to 3 of the raw herbs. Doses of
Herba Epimedii and Fructus Ligustri Lucidi were chosen
based on the clinical practice by Shi-Zeng Li (21 g/kg in
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which have demonstrated effective prevention and treat-
ment of osteoporosis. Before application, the TFE and
TIFL mixtures were dissolved in deionized water at con-
centrations of 5, 10, and 20 mg/mL.
Animals
Fifty male Wistar rats weighing 230–270 g with an aver-
age age of 3 months were purchased from Vital River
Laboratory Animal Technology Co. Ltd. (Beijing, China)
and cared for in the Experimental Animal Center of
Capital Medical University. The experimental protocol
was approved by the Animal Research Committee of
Capital Medical University. During the entire experi-
ment, the animals were housed in stainless cages (three
rats per cage) under conventional controlled conditions
(temperature: 23 ± 2°C, relative humidity: 50 ± 10%, and
12-hour light–dark cycle). They were allowed free access
to the standard laboratory food and tap water.
Experimental protocol
After acclimatization for 1 week, the rats were randomly
divided into five groups of 10 rats each, including a nor-
mal control group, osteoporosis model group, and low
(Extract-L, 50 mg/kg/day), medium (Extract-M, 100 mg/
kg/day), and high (Extract-H, 200 mg/kg/day) treatment
groups. All rats except those in the normal control
group received intragastric administration of retinoic
acid (70 mg/kg) daily for 2 weeks to induce the osteo-
porosis model. The rats in the treatment groups were
administered the combined extracts via oral gavage at
the indicated doses. The rats in the normal control
group and osteoporosis model group were given oral
gavage with the same volume of distilled water. Three
weeks later, the rats were anesthetized with 25% ethyl
carbamate (4 mL/kg, i.p.). Blood samples were collected
and separated using a centrifuge (Biofuge 15R, Heraeus
Sepatech, Baxter International, Deerfield, IL, USA).
Serum was collected and stored at −80°C until detection
of bone turnover markers, calcium, and phosphorus.
The right femur and tibia were isolated, wrapped in
gauze soaked in 0.9% NaCl solution, and stored at −20°C.
Serum markers of bone turnover
The serum levels of bone turnover markers, including
osteocalcin, alkaline phosphatase (ALP), tartrate-resistant
acid phosphatase (TRACP), procollagen type I carboxy-
terminal propeptide (PICP), procollagen type I amino-
terminal propeptide (PINP), and carboxy-terminal cross
linked telopeptide of type I collagen (CTX), were deter-
mined. Serum osteocalcin was measured in duplicate using
an osteocalcin radioimmunoassay kit (Beijing Sino-UK In-
stitute of Biological Technology, Beijing, China). Serum
ALP level was assayed using a commercial kit (NanjingJiancheng Bioengineering Institute, Nanjing, China) with a
spectrophotometer (Shimadzu, Kyoto, Japan). Serum
TRACP, PICP, PINP, and CTX were measured by enzyme-
linked immunosorbent assays (Immunodiagnostic Systems
Ltd., Boldon, UK) with the absorbance read on an ELISA
reader (Thermo, Waltham, MA, USA) at 450 nm.
Bone biomechanical testing
The biomechanical properties of the right femur were
assessed using a diaphysis bending test [18] on a WD-1
Universal Testing Apparatus (KeXin Testing Machine
Co., Ltd., Changchun, China) that was equipped with
calculation and analysis software. The two ends of the
right femur were horizontally fixed on the three-point
bending platform, and a vertical compression load was
then applied to the mid-point of the femur at a displace-
ment rate of 2 mm/min. The Loading-displacement
curves were recorded on-line and analyzed to determing
the bone biomechanical properties of ultimate load (the
force at which fracture occurs) and displacement at ultimat
(bone deformation at the fracture point)..
Bone mineral content
Serum levels of calcium and phosphorus were determined
by colorimetric analysis using a calcium reagent set and a
phosphorus reagent set (Nanjing Jiancheng Bioengineering
Institute) with a spectrophotometer (Shimadzu).
To determine the mass of bone mineral, the right
tibia sample was weighed (wet weight), and then dried
at 640°C for 12 hours in a muffle furnace. The dried
sample was ground into powder and weighed (dry
weight). The ratio of the bone mineral mass to the
bone mass was determined. One hundred milligrams of
bone powder was then dissolved in 6 M HCl and diluted
with distilled water. The calcium and phosphorus contents
were measured using atomic absorption spectrophotometry
(Analyst 100 Spectrophotometer, PerkinElmer, Waltham,
MA, USA).
Statistical analysis
Data are presented as means ± standard deviation (SD).
The data analysis was performed in SPSS 13.0 (SPSS
Inc., Chicago, IL, USA). All of the data were tested for
normality using the Kolmogorov–Smirnov test and
passed. Differences between the groups were tested
using analysis of variance followed by Duncan’s multiple
range post-hoc test. P-values less than 0.05 were consid-
ered statistically significant.
Results
Serum markers of bone turnover
The levels of serum markers of bone turnover, including
osteocalcin, ALP, TRACP, PICP, PINP, and CTX, all of
which were significantly higher in the osteoporosis model
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Figure 1. Treatment with the combination of TFE and
TIFL significantly decreased the osteocalcin and PICP
contents compared with those of the osteoporosis group.
In addition, the concentrations of ALP and TRACP were
significantly decreased in the Extract-M and Extract-HFigure 1 Effects of the combination with TFE and TIFL on osteocalcin
osteoporosis rats. serum markers of bone turnover, including osteocalcin
in the osteoporosis model group than those in the normal control group.
model group.groups, while the levels of PINP and CTX were decreased
only in the Extract-H group.
Bone biomechanical properties
The results of biomechanical testing are shown in Figure 2.
The femur ultimate load and displacement at ultimate(A), ALP (B), TRACP (C), PICP (D), PINP (E) and CTX (F) in
, ALP, TRACP, PICP, PINP and CTX, all of which were significantly greater
Mean ± SD, n = 10. *P < 0.05 and **P < 0.01 vs osteoporosis
Figure 2 Effects of the combination with TFE and TIFL on
ultimate load (A) and displacement at ultimate (B) of femur
biomechanical properties in osteoporosis rats. Femur ultimate
load and displacement at ultimate were significantly decreased in
the osteoporosis model group, compared to the normal control
group. Mean ± SD, n = 10. *P < 0.05 and **P < 0.01 vs osteoporosis
model group.
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the normal control group. Significant differences in the
biomechanical properties of the right femur were found
between the osteoporosis group and each of the groups
treated with the TFE and TIFL combination.Bone mineral content
The bone mineral contents are shown in Figure 3. No
effects of the combined TFE and TIFL treatment on the
serum levels of calcium and phosphorus were found.
The comparative bone mass (the ratio of bone mass to
body mass), comparative mineral mass (the ratio of min-
eral mass to bone mass),, bone calcium, and bone phos-
phorus in the osteoporotic rats were significantly lower
than those in the normal group (all P < 0.01). Treatment
with the TFE and TIFL combination at all three doses
significantly increased the comparative mineral mass
and calcium content in the right tibia compared to those
in the osteoporotic rats. In addition, the 200 mg/kg doseincreased the comparative bone mass compared to that
in the osteoporosis model group.Discussion
The kidney-tonifying Chinese herbal medicines Herba
Epimedii and Fructus Ligustri Lucidi have been widely
used to treat bone disease for thousands of years in
China. Professor Shi-Zeng Li, a famous doctor of TCM,
has used the decoction composed of Herba Epimedii (as
a kidney-Yang tonifying herb) and Fructus Ligustri
Lucidi (as a kidney-Yin tonifying herb) to treat osteopor-
osis for almost 50 years. Preliminary studies from our
group confirmed that the decoction and combined ex-
tracts of Herba Epimedii and Fructus Ligustri Lucidi
showed anti-osteoporotic effects on retinoic acid-
induced model of osteoporosis in rats [11]. In fact, the
effect of the combined Herba Epimedii and Fructus
Ligustri Lucidi therapy was significantly better than ei-
ther one alone, suggesting that the combination of the
two herbs may be good for the prevention and treatment
of osteoporosis. These two herbal medicines will un-
doubtedly continue to be used as a cost-effective alterna-
tive to commercial pharmaceuticals for the treatment of
osteoporosis by doctors of TCM. However, the effects of
the combined extracts of the two herbs for managing
osteoporosis have not yet been fully reported. Based on
several previous studies elucidating the active ingredients
of Herba Epimedii and Fructus Ligustri Lucidi, we chose
TFE and TIFL from among the active ingredients of the
two herbs in this study for further evaluation of their
anti-osteoporosis effects.
Biochemical markers of bone turnover provide import-
ant indications for the early diagnosis of osteoporosis
and reflect bone formation and resorption through the
bone turnover rate [19]. ALP and osteocalcin are bio-
chemical markers of osteogenesis [20,21], while TRACP
is a marker of bone resorption [22,23]. Retinoic acid-
induced osteoporosis model is a high bone turnover type
of osteoporosis characterized by large increases in bone
formation and bone resorption. However, the increase in
bone resorption is larger than that of bone formation,
leading to significant changes in bone turnover resulting
in a net bone loss [24]. The higher levels of ALP, TRACP,
and osteocalcin in the osteoporosis model group reflect
the increase in bone formation that accompanies the
excessive increase in bone resorption that normally ap-
pears in high conversion-type osteoporosis. After adminis-
tration of the combined TFE and TIFL for 3 weeks, the
levels of ALP, TRACP, and osteocalcin were lower than
those of the osteoporosis model group. This suggests that
the extracts of the two herbs may help prevent osteopor-
osis by mitigating the high turnover rate of osteoporotic
bone metabolism.
Figure 3 Effects of the combination with TFE and TIFL on bone mineral contents in osteoporosis rats, including serum calcium (A),
serum phosphorus (B), the ratio of bone mass to body mass (C), the ratio of mineral mass to bone mass (D), bone calcium (E) and
bone phosphorus (F). Bone mass/body mass ratio, mineral mass/bone mass ratio, bone calcium and bone phosphorus in the osteoporosis
model group were significantly lower than those in the normal group. Mean ± SD, n = 10. *P < 0.05 and **P < 0.01 vs osteoporosis model group.
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ating osteoblastic cells and comprises more than 90% of
the organic matrix of mineralized bone. The higher con-
centrations of the formation and degradation markers of
type I collagen suggest “catch-up growth” of bone collagenmatrix and normalization of the bone collagen turnover
[25]. PINP and PICP are markers of the formation of the
organic matrix of bone and type I collagen synthesis [26].
Serum PINP is reported to be more sensitive than serum
PICP to changes in bone turnover [27], but CTX, a marker
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tive marker for bone resorption and bone collagen degrad-
ation [28,29]. The results of the present study show that
the serum PINP, PICP, and CTX levels in the osteoporosis
model group were significantly larger than those in the
normal control group, while the combined extracts of
Herba Epimedii and Fructus Ligustri Lucidi significantly
decreased the serum levels of PINP, PICP, and CTX. These
results suggest that the active ingredients in the two herbs
may effectively regulate collagen metabolism and bone
turnover in osteoporotic rats.
Osteoporosis causes incremental bone fragility, in-
creased fracture risk, and decreased bone mass [30-32].
After treatment with the combined TFE and TIFL, in-
creases in the bone mechanical properties, including
ultimate load and displacement at ultimate, were mea-
sured. These results indicate the combined extracts of
the two herbs could improve the bone biomechanical
features, and decrease the fracture risk. The primary
change in bone mass during osteoporosis is an increase
in the loss of calcium from the skeleton. Because of the
rapid bone loss, the secretion of parathyroid hormone
decreases, which in turn decreases calcium absorption
in the intestine, finally resulting in the loss of calcium
from the bone and body [33,34]. In the present experi-
ments, treatment with the combined TFE and TIFL de-
creased the progression of osteoporosis, as assessed by the
bone calcium content and mineral mass. We speculate
that the increase in the bone calcium content may have
been caused by the high intake of sugars that are present
in the combined extracts. Some of the sugars may have
reached the gastrointestinal tract and been fermented by
the intestinal bacteria, reducing the pH of the environ-
ment and increasing calcium absorption. Such a mech-
anism was proposed for inulin-type fructans, which
were reported to increase calcium absorption [35]. This
increased calcium absorption was accompanied by an
increased mineral mass in the bones of rats fed a diet
containing fructooligosaccharides [36].
The detailed compositions of both Herba Epimedii
and Fructus Ligustri Lucidi have been previously re-
ported, and mainly include flavonoids, iridoid glycosides,
and alkaloids, all of which may contribute to the anti-
osteoporotic effects of the two herbs. The total flavo-
noids from Herba Epimedii are reported to protect
against bone loss, including by maintaining the calcium
metabolism balance [14], promoting the proliferation of
osteoblasts, and suppressing bone resorption [13]. Icariin,
Icariside II, and Baohuoside from Herba Epimedii sig-
nificantly inhibited the proliferation of pre-osteoclast
RAW 264.7 cells [13], and synergistic inhibition activity
of Icariside II and Icaritin was found [37]. Similarly, the
total iridoids and flavonoids from Fructus Ligustri
Lucidi showed therapeutic effects on the BMD andabsorption of intestinal calcium [15-17]. The ethanol
extracts of Fructus Ligustri Lucidi are able to modulate
the turnover of bone, calcium balance, and bone proper-
ties, as well as enhance the mineralization process [38,39].
These results suggested that the anti-osteoporotic effects
of the combined extracts of Epimedii and Fructus Ligustri
Lucidi may be the result of cooperative action among mul-
tiple compounds with their multiple components working
together to common affect. The exact roles of the different
active components when used for treatment of osteopor-
osis remain to be further investigated.
Conclusions
The combination of extracts from Herba Epimedii and
Fructus Ligustri Lucidi demonstrated potential as a pro-
tective treatment for retinoic acid-induced osteoporosis in
rats. The mechanism controlling the anti-osteoporosis ef-
fects of the combined extracts may involve the synergistic
inhibitory effects on bone formation and bone resorption,
thereby reducing the high turnover rate of osteoporotic
bone metabolism. In addition, the combined extracts may
be able to enhance the bone biomechanical properties and
increase the bone mineral content.
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